

Vascular lesions in MASLD pathogenesis: clinical data and implications

ASSISTANCE

PUBLIQUE

HÔPITAUX

DE PARIS

Pierre-Emmanuel RAUTOU

Inserm U1149, Centre de recherche sur l'inflammation, Paris Service d'hépatologie, Hôpital Beaujon, Clichy, France

pierre-emmanuel.rautou@inserm.fr






Institut national de la santé et de la recherche médicale




Université Paris Cité


Vascular lesions in MASLD pathogenesis

- What changes occur in endothelial cells in MASLD?
- What causes those changes?
- What are the consequences?
- MASLD and portal hypertension





Capillarization precedes MASH: CD34 staining in patients No SLD MASLD




Lobular score: 0/3, Periportal score 1/3

Lobular score: 1/3, Periportal score 1/3

38 patients considered for inclusion in the NATIVE trial CD34 staining


Capillarization precedes MASH: CD34 staining in patients




38 patients considered for inclusion in the NATIVE trial CD34 staining


Vascular lesions in MASLD pathogenesis

- What changes occur in endothelial cells in MASLD?
- What causes those changes?
- What are the consequences?
- MASLD and portal hypertension






Capillarisation and steatosis: no link in patients




248 patients considered for inclusion in the NATIVE trial CD34 staining

Capillarisation and ballooning: no link in patients



248 patients considered for inclusion in the NATIVE trial CD34 staining



Portal blood contains elevated IL-6 concentrations in obese patients

Adipokine	Sample site	
	Radial artery	Portal vein
IL-6 (pg/ml)	28.5 ± 27.6	$42.1 \pm 41.8^*$
TNF-α (pg/ml)	1.87 ± 0.8	1.93 ± 0.8
MCP-1 (pg/ml)	205 ± 88	190 ± 99
Resistin (pg/ml)	18.5 ± 11	18.1 ± 11
Leptin (ng/ml)	101 ± 51	$81 \pm 42^{+}$
Total adiponectin (µg/ml)	14.3 ± 10	14.7 ± 11


N=25; by-pass surgery

Fontana, et al. Diabetes 2007

Vascular lesions in MASLD pathogenesis


- What changes occur in endothelial cells in MASLD?
- What causes those changes?
- What are the consequences?
- MASLD and portal hypertension

LSEC capillarization and liver inflammation in patients with MASLD



248 patients considered for inclusion in the NATIVE trial CD34 staining

LSEC capillarisation and liver fibrosis in patients with MASLD




248 patients considered for inclusion in the NATIVE trial CD34 staining

Vascular lesions in MASLD pathogenesis

- What changes occur in endothelial cells in MASLD?
- What causes those changes?
- What are the consequences?
- MASLD and portal hypertension


Patients with MASLD do not have severe portal hypertension in the absence of cirrhosis



Moga L, et al. J Hepatol 2021 (Collab C. Bureau)


Decompensation in MASLD may occur at lower HVPG

548 patients with NAFLD and 444 with HCV (F3-F4)



Bassegoda O*, Pol O*, et al., Clin Gastroenterol Hepatol. 2022

HVPG predicts liver related complications in MASLD



Conclusion

• Sinusoid Capillarisation in MASLD:

✓ Occurs before MASH

- ✓ Does not seem to favor steatosis nor ballooning
- \checkmark Increases with inflammation and fibrosis

• Portal hypertension in MASLD:

- ✓ May occur at F1-F2 fibrosis
- \checkmark Is only severe in patients with cirrhosis
- ✓ May lead to decompensation at lower HVPG level





Institut national de la santé et de la recherche médicale



Inserm U1149 - ATIP AVENIR, www.rautoulab.com/





Hepatology unit, Beaujon Hospital Reference center for vascular liver diseases



Les Programmes Hospitaliers de Recherche Clinique (PHRC)





Get these slides:

